Manufacturers decide to cease further development of mirikizumab in psoriasis

This IL23 inhibitor demonstrated superiority to placebo, and non-inferiority to secukinumab in the Phase III OASIS-2 study, but manufacturers do not plan to make market authorisation applications as psoriasis is a very crowded market.

Biospace Inc.